CTSW is pleased to have represented Ocuvex Therapeutics, Inc., a biopharmaceutical company specializing in ophthalmic therapeutics, in its Merger Agreement with Onconetix, Inc. (Nasdaq: ONCO). Under the Merger Agreement, Onconetix will acquire all Ocuvex equity interests in exchange for newly-issued Onconetix shares, resulting in Ocuvex equity holders owning 90% of the combined company, subject to certain adjustments. The transaction was announced on July 16, 2025, and is expected to close in the fourth quarter of 2025, subject to customary closing conditions and regulatory approvals.
For further details, please see the press release.